FoodSep 17, 2025
Wegmans Grilling Camembert with Tapenade & Roasted Tomatoes recall — FDA H-0571-2025
Products may be contaminated with Listeria monocytogenes
Class IFDA: TerminatedWegmans Food Markets, Inc.
September 2025 recalls — page 3
These records include useful source details for the selected month.
FoodSep 17, 2025
M.O.M Enterprises, LLC Organic BABY bedtime drops recall — FDA H-0576-2025
Potential for spoilage due to yeast contamination.
Class IIFDA: OngoingM.O.M Enterprises, LLC.
DrugSep 17, 2025
Sulfamethoxazole and Trimethoprim, USP, 800 mg/160 mg, Double Strength, 100 Tablets unit recall — FDA D-0624-2025
Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a…
Class IIFDA: OngoingThe Harvard Drug Group LLC dba Major Pharmaceuticals…
DrugSep 17, 2025
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and recall — FDA D-0642-2025
Presence of Foreign Tablet/Capsule: Two (2) bottles labeled as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 10mg, 100ct,…
Class IIFDA: CompletedLannett Company Inc.
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 100-count bottle recall — FDA D-0631-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
Sulfamethoxazole and Trimethoprim, USP, 800 mg/160 mg, Double Strength, 10 Tablets unit dose recall — FDA D-0625-2025
Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a…
Class IIFDA: OngoingThe Harvard Drug Group LLC dba Major Pharmaceuticals…
DrugSep 17, 2025
Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle recall — FDA D-0621-2025
CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
Class IIFDA: OngoingBreckenridge Pharmaceutical, Inc.
DrugSep 17, 2025
SODIUM BICARBONATE 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For recall — FDA D-0620-2025
Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.
Class IIFDA: OngoingExela Pharma Sciences LLC
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 200 mg, 100-count bottle recall — FDA D-0638-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
GRACE & FIRE PTY Ultra Violette, Velvet Screen SPF 50, Blurring Mineral Skinscreen, Zinc recall — FDA D-0640-2025
Subpotent/Super-potent Product: Testing of the SPF 50 sunscreen revealed inconsistency in SPF results ranging from SPF 4, 10, 21, 26, 33, 60, 61, and 64.
Class IIFDA: OngoingGRACE & FIRE PTY LTD
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 100 mg, 100-count bottle recall — FDA D-0636-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
Succinylcholine Chloride Injection, USP 200 mg/10 mL (20 mg/mL) recall — FDA D-0623-2025
Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
GRACE & FIRE PTY Ultra Violette Mini SPF Mates kit includes: Velvet Screen SPF 50 Blurring recall — FDA D-0641-2025
Subpotent/Super-potent Product: Testing of the SPF 50 sunscreen revealed inconsistency in SPF results ranging from SPF 4, 10, 21, 26, 33, 60, 61, and 64.
Class IIFDA: OngoingGRACE & FIRE PTY LTD
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 50 mg, 100-count bottle recall — FDA D-0635-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 200 mg, 100-count bottle recall — FDA D-0639-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 25 mg, 100-count bottle recall — FDA D-0632-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 25 mg, 100-count bottle recall — FDA D-0633-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 100 mg, 100-count bottle recall — FDA D-0637-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 100-count bottle recall — FDA D-0630-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugSep 17, 2025
Chlorpromazine Hydrochloride Tablets, USP, 50 mg, 100-count bottle recall — FDA D-0634-2025
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
VehicleSep 11, 2025
Toyota Motor Engineering & Manufacturing instrument cluster/panel recall — NHTSA campaign 25V595000
Toyota Motor Engineering & Manufacturing (Toyota) is recalling certain 2023-2024 Toyota Venza, 2023-2025 RAV4 Prime, RAV4, Highlander, GR Corolla, Crown, 2024-2025 Lexus TX, LS, Toyota…
instrument cluster/panelToyota Motor Engineering & Manufacturing
FoodSep 10, 2025
The Candy Barn Chocolate Pecan Fudge, The Candy Barn, 1113 Palm Ave recall — FDA H-0562-2025
Allergen labeling: specific tree nut (pecan) and egg are not listed in the 'contains' statement
Class IIFDA: TerminatedThe Candy Barn
FoodSep 10, 2025
The Candy Barn Pecan Toffee Clusters, The Candy Barn, 1113 Palm Ave recall — FDA H-0567-2025
Allergen labeling: specific tree nut (pecan) not listed in 'contains' statement
Class IIFDA: TerminatedThe Candy Barn
FoodSep 10, 2025
The Candy Barn Chocolate Mint Fudge, The Candy Barn, 1113 Palm Ave Riverside recall — FDA H-0561-2025
Allergen labeling: egg is not listed in the 'contains' statement
Class IIFDA: TerminatedThe Candy Barn
How to use this monthly recall archive
Use this page to compare the recalls reported during the month, then open an individual record for the exact reason, classification, company, remedy or distribution information available from the official source. Monthly counts are descriptive, not a safety rating.